These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 4850260)
1. A perspective on drug reaction reporting. Schneller GH Am J Pharm Sci Support Public Health; 1974; 146(3):70-4. PubMed ID: 4850260 [No Abstract] [Full Text] [Related]
2. Package inserts, adverse drug reactions, and the physician's liability. Morrell MX Ration Drug Ther; 1975 Aug; 9(8):1-6. PubMed ID: 1144773 [No Abstract] [Full Text] [Related]
3. When pharmacist and physician disagree. Lacina N Prog Clin Biol Res; 1983; 139():211-21. PubMed ID: 6669544 [No Abstract] [Full Text] [Related]
4. Developing an adverse drug reaction reporting program. Nelson RW; Shane R Am J Hosp Pharm; 1983 Mar; 40(3):445-6. PubMed ID: 6846354 [No Abstract] [Full Text] [Related]
5. How pharmacists can speed new drug approval through ADR reporting. Kennedy D Pharm Times; 1978 Mar; 44(3):44-8. PubMed ID: 10307082 [No Abstract] [Full Text] [Related]
6. The black box warning. Abourjaily HM; Rosenberg M J Mass Dent Soc; 2002; 51(3):54-6. PubMed ID: 12380043 [No Abstract] [Full Text] [Related]
7. Hospital pharmacy program for reporting adverse drug reactions. Jacinto MS; Kleinmann K Am J Hosp Pharm; 1983 Mar; 40(3):444-5. PubMed ID: 6846353 [No Abstract] [Full Text] [Related]
8. Reporting adverse drug reaction in a small hospital. Magee PE; Garrison TJ Hospitals; 1976 Jan; 50(2):63-4, 66-7. PubMed ID: 1245331 [No Abstract] [Full Text] [Related]
9. The pharmacist and adverse drug reaction reporting. Pearson K Hosp Pharm; 1982 Aug; 17(8):421-2, 427-30. PubMed ID: 10256700 [TBL] [Abstract][Full Text] [Related]
10. Food and Drug Administration's adverse drug reaction monitoring program. Lee B; Turner WM Am J Hosp Pharm; 1978 Aug; 35(8):929-32. PubMed ID: 677138 [TBL] [Abstract][Full Text] [Related]
12. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
13. Target: adverse drug reactions. Welsh JS Am Pharm; 1979 Aug; 19(9):30-3. PubMed ID: 506916 [No Abstract] [Full Text] [Related]
14. ASHP statement on the use of medications for unlabeled uses. Am J Hosp Pharm; 1992 Aug; 49(8):2006-8. PubMed ID: 1442846 [No Abstract] [Full Text] [Related]
15. The need for pharmacists' cooperation in national adverse drug reaction reporting. Lee B; Groth PE Hosp Formul; 1978 Nov; 13(11):888-91, 895. PubMed ID: 10239344 [No Abstract] [Full Text] [Related]
16. When pharmacist and physician disagree. Shea M Prog Clin Biol Res; 1983; 139():203-9. PubMed ID: 6669543 [No Abstract] [Full Text] [Related]
17. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Beach JE; Faich GA; Bormel FG; Sasinowski FJ Food Drug Law J; 1998; 53(3):403-11. PubMed ID: 10346718 [No Abstract] [Full Text] [Related]
18. Liability for adverse drug reactions. Francisco CJ Tex Med; 1990 May; 86(5):42-6. PubMed ID: 2343420 [TBL] [Abstract][Full Text] [Related]
19. The medicolegal aspects of adverse drug reactions. Bernstein HN; Levine AM Int Ophthalmol Clin; 1970; 10(3):455-72. PubMed ID: 5537801 [No Abstract] [Full Text] [Related]
20. Point of law: what are the legal implications of prescribing and administering FDA-approved drugs in nonapproved ways? Kaunitz AM Hosp Med Staff; 1982 Feb; 11(2):15-8. PubMed ID: 10254209 [No Abstract] [Full Text] [Related] [Next] [New Search]